Recent Advances of Therapeutic Targets for the Treatment of Periodontal Disease

• Published in: Biomolecules & therapeutics Vol. 29; no. 3; pp. 263 - 267
• Main Authors: Kim, Woo Jin, Soh, Yunjo, Heo, Seok-Mo
• Format: Journal Article
• Language: Korean
• Published: 한국응용약물학회 01-05-2021
• Subjects: Inflammasome; Parathyroid hormone; Periodontitis; Quorum sensing and quenching; Sclerostin antibody; Teriparatide; Sclerostin antibody; Inflammasome; Periodontitis; Quorum sensing and quenching; Parathyroid hormone; Teriparatide
• ISSN: 1976-9148; 2005-4483

Periodontal disease is primarily associated with bacterial infection such as dental plaque. Dental plaque, an oral biofilm harboring a complex microbial community, can cause various inflammatory reactions in periodontal tissue. In many cases, the local bacterial invasion and host-mediated immune responses lead to severe alveolar bone destruction. To date, plaque control, non-surgical, and surgical interventions have been the conventional periodontal treatment modalities. Although adjuvant therapies including antibiotics or supplements have accompanied these procedures, their usage has been limited by antibiotic resistance, as well as their partial effectiveness. Therefore, new strategies are needed to control local inflammation in the periodontium and host immune responses. In recent years, target molecules that modulate microbial signaling mechanisms, host inflammatory substances, and bone immune responses have received considerable attention by researchers. In this review, we introduce three approaches that suggest a way forward for the development of new treatments for periodontal disease; (1) quorum quenching using quorum sensing inhibitors, (2) inflammasome targeting, and (3) use of FDA-approved anabolic agents, including Teriparatide and sclerostin antibody.